Physician profile
Patrick C Mannebach
NPI 1801971221
$4,155.88
in general payments reported to CMS, 2019-2025
36 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.63 · 2020: $47.41 · 2021: $322 · 2022: $702 · 2023: $971 · 2024: $1,049 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.87 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $800.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $485.68 | 2021-2024 | Xarelto |
| Amgen INC. | $295.27 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $262.59 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.14 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $207.92 | 2019-2025 | Triclip, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic, INC. | $169.84 | 2023 | Symplicity G3 |
| Alnylam Pharmaceuticals INC. | $162.53 | 2021-2024 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $155.19 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $147.17 | 2022-2023 | Opsumit, Uptravi |
| Heartflow, INC. | $119.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.47 | 2020-2024 | Jardiance |
| Novo Nordisk INC | $103.54 | 2022-2024 | Ozempic, Wegovy |
| Boston Scientific Corporation | $86.47 | 2022-2025 | Watchman Access System |
| Cleerly, INC. | $75.39 | 2025 | Cleerly Labs, Cleerly Ischemia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.53 | 2022-2025 | Verquvo |
| Astellas Pharma US INC | $62.36 | 2019-2022 | |
| Daiichi Sankyo INC. | $62.08 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $51.37 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $50.21 | 2024 | Inpefa |
| United Therapeutics Corporation | $49.93 | 2024-2025 | Tyvaso, Tyvaso |
| Abiomed | $38.36 | 2024-2025 | Impella |
| Esperion Therapeutics, INC. | $37.74 | 2021 | |
| Csl Behring | $37.14 | 2023 | Kcentra |
| Edwards Lifesciences Corporation | $34.79 | 2022 | |
| Scpharmaceuticals INC. | $34.39 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.26 | 2021-2025 | |
| Chiesi USA, INC. | $27.85 | 2021-2022 | |
| Amarin Pharma, INC. | $27.14 | 2021 | |
| Bridgebio Pharma, INC. | $21.80 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.68 | 2025 | Lifevest |
| Genzyme Corporation | $18.26 | 2025 | |
| Atricure, INC. | $16.51 | 2025 | Atriclip Laa Exclusion System |
| Kiniksa Pharmaceuticals International, Plc | $14.80 | 2024 | Arcalyst |
| G Medical Diagnostic Services, INC. | $13.94 | 2022 | |
| Acarix USA INC. | $10.90 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mannebach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.